Revolution Medicines' Mancini sells 2,310 shares

The chief global commercialization officer's option exercise and sale were made under a Rule 10b5-1 trading plan adopted June 11, 2026.

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Global Commercialization Officer Anthony Mancini exercised options to acquire 2,310 common shares at an exercise price of $33.62 and sold 2,310 shares at $186.99 on October 26, 2026. These transactions were made under a Rule 10b5-1 trading plan adopted June 11, 2026. The reported post-transaction amount for the stock option was 91,315 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,310 shares ($354K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Mancini Anthony

Role See Remarks

Sold 2,310 shs ($432K)

Approx. gross sale proceeds $432K

Approx. exercise cost $78K

Approx. pre-tax spread $354K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	2,310	$0.00	$0.00
Exercise	Common Stock F1	2,310	$33.62	$78K
Sale	Common Stock F1, F2	2,310	$186.99	$432K

Holdings After Transaction: Stock Option (Right to Buy) — 91,315 contracts (Direct); Common Stock — 39,765 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
2. F2. Includes 39,575 restricted stock units.
3. F3. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Shares acquired through option exercise: 2,310 shares Option exercise price: $33.62 per share Shares sold: 2,310 shares +2 more

5 metrics

Shares acquired through option exercise 2,310 shares October 26, 2026

Option exercise price $33.62 per share Options exercised October 26, 2026

Shares sold 2,310 shares October 26, 2026

Sale price $186.99 per share Shares sold October 26, 2026

Post-transaction stock option amount 91,315 shares Reported after the October 26, 2026 transaction

Key Terms

Rule 10b5-1 trading plan, restricted stock units, Vesting Commencement Date, fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 39,575 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date financial

"the Vesting Commencement Date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable financial

"fully vested and exercisable as of the fourth anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RVMD shares did Anthony Mancini acquire and sell, and at what prices?

Anthony Mancini exercised options to acquire 2,310 common shares at $33.62 and sold 2,310 shares at $186.99 on October 26, 2026. These transactions were made under a Rule 10b5-1 trading plan adopted June 11, 2026.

What is the vesting schedule for Anthony Mancini's RVMD options?

Twenty-five percent of the shares subject to the option vest on the first anniversary of April 1, 2025, and 1/48 vests on each monthly anniversary thereafter. The option is fully vested and exercisable on the fourth anniversary, subject to continued service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 06:00 PM EDT Accepted by SEC EDGAR 10/28/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/26/2026		M(1)		2,310	A	$33.62	42,075	D
Common Stock	10/26/2026		S(1)		2,310	D	$186.99	39,765(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.62	10/26/2026		M(1)			2,310	(3)	04/01/2035	Common Stock	106,109	$0	91,315	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

2. Includes 39,575 restricted stock units.

3. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)